<VariationArchive VariationID="661743" VariationName="NC_000016.10:g.(?_13920156)_(13948357_?)del" VariationType="Deletion" Accession="VCV000661743" Version="6" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-10" DateCreated="2019-08-14" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="652453" VariationID="661743">
      <GeneList>
        <Gene Symbol="ERCC4" FullName="ERCC excision repair 4, endonuclease catalytic subunit" GeneID="2072" HGNC_ID="HGNC:3436" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16p13.12</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="13920154" stop="13952348" display_start="13920154" display_stop="13952348" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="14014013" stop="14046204" display_start="14014013" display_stop="14046204" Strand="+" />
          </Location>
          <OMIM>133520</OMIM>
        </Gene>
        <Gene Symbol="LOC130058543" FullName="ATAC-STARR-seq lymphoblastoid active region 10486" GeneID="130058543" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>16p13.12</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="13919998" stop="13920357" display_start="13919998" display_stop="13920357" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="LOC130058544" FullName="ATAC-STARR-seq lymphoblastoid active region 10487" GeneID="130058544" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>16p13.12</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="13920398" stop="13920607" display_start="13920398" display_stop="13920607" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NC_000016.10:g.(?_13920156)_(13948357_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16p13.12</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" innerStart="13920156" innerStop="13948357" display_start="13920156" display_stop="13948357" variantLength="28202" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" innerStart="14014013" innerStop="14042214" display_start="14014013" display_stop="14042214" variantLength="28202" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.(?_13920156)_(13948357_?)del" Assembly="GRCh38">
            <Expression>NC_000016.10:g.(?_13920156)_(13948357_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.(?_14014013)_(14042214_?)del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.(?_14014013)_(14042214_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000016.10:g.(?_13920156)_(13948357_?)del AND multiple conditions" Accession="RCV000819225" Version="6">
        <ClassifiedConditionList TraitSetID="31137">
          <ClassifiedCondition DB="MedGen" ID="C0009207">Cockayne syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3808988">Fanconi anemia complementation group Q</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268140">Xeroderma pigmentosum, group F</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-07-26" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2018-07-26" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2019-08-14" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">9580660</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="31137" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17953" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia complementation group Q</ElementValue>
                <XRef ID="MONDO:0014108" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FANCQ</ElementValue>
                <XRef Type="MIM" ID="615272" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15934" />
                <XRef ID="15934" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C3808988" DB="MedGen" />
              <XRef ID="MONDO:0014108" DB="MONDO" />
              <XRef Type="MIM" ID="615272" DB="OMIM" />
            </Trait>
            <Trait ID="4031" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP F</ElementValue>
                <XRef Type="MIM" ID="278760" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Xeroderma pigmentosum, group F</ElementValue>
                <XRef ID="Xeroderma+pigmentosum%2C+group+F/9524" DB="Genetic Alliance" />
                <XRef ID="42530008" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">XERODERMA PIGMENTOSUM, TYPE F</ElementValue>
                <XRef Type="Allelic variant" ID="133520.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="133520.0001" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Xeroderma pigmentosum, type 6</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">XERODERMA PIGMENTOSUM VI</ElementValue>
                <XRef Type="MIM" ID="278760" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">XP, GROUP F</ElementValue>
                <XRef Type="MIM" ID="278760" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">XP6</ElementValue>
                <XRef Type="MIM" ID="278760" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">XPF</ElementValue>
                <XRef Type="MIM" ID="278760" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5628" />
                <XRef ID="5628" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Xeroderma pigmentosum (XP) is characterized by: Acute sun sensitivity (severe sunburn with blistering, persistent erythema on minimal sun exposure) with marked freckle-like pigmentation of the face before age two years; Sunlight-induced ocular involvement (photophobia, severe keratitis, atrophy of the skin of the lids, ocular surface neoplasms); Greatly increased risk of sunlight-induced cutaneous neoplasms (basal cell carcinoma, squamous cell carcinoma, melanoma) within the first decade of life. Approximately 25% of affected individuals have neurologic manifestations (acquired microcephaly, diminished or absent deep tendon stretch reflexes, progressive sensorineural hearing loss, progressive cognitive impairment, and ataxia). The most common causes of death are skin cancer, neurologic degeneration, and internal cancer. The median age at death in persons with XP with neurodegeneration (29 years) was found to be younger than that in persons with XP without neurodegeneration (37 years).</Attribute>
                <XRef ID="NBK1397" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301571</ID>
                <ID Source="BookShelf">NBK1397</ID>
              </Citation>
              <XRef ID="C0268140" DB="MedGen" />
              <XRef ID="MONDO:0010215" DB="MONDO" />
              <XRef Type="MIM" ID="278760" DB="OMIM" />
            </Trait>
            <Trait ID="6530" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Cockayne syndrome</ElementValue>
                <XRef ID="MONDO:0016006" DB="MONDO" />
                <XRef ID="21086008" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cockayne's syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Dwarfism-retinal atrophy-deafness syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Progeria-like syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Progeroid nanism</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Cockayne syndrome (referred to as CS in this GeneReview) spans a continuous phenotypic spectrum that includes: CS type I, the "classic" or "moderate" form; CS type II, a more severe form with symptoms present at birth; this form overlaps with cerebrooculofacioskeletal (COFS) syndrome; CS type III, a milder and later-onset form; COFS syndrome, a fetal form of CS. CS type I is characterized by normal prenatal growth with the onset of growth and developmental abnormalities in the first two years. By the time the disease has become fully manifest, height, weight, and head circumference are far below the fifth percentile. Progressive impairment of vision, hearing, and central and peripheral nervous system function leads to severe disability; death typically occurs in the first or second decade. CS type II is characterized by growth failure at birth, with little or no postnatal neurologic development. Congenital cataracts or other structural anomalies of the eye may be present. Affected children have early postnatal contractures of the spine (kyphosis, scoliosis) and joints. Death usually occurs by age five years. CS type III is a phenotype in which major clinical features associated with CS only become apparent after age two years; growth and/or cognition exceeds the expectations for CS type I. COFS syndrome is characterized by very severe prenatal developmental anomalies (arthrogryposis and microphthalmia).</Attribute>
                <XRef ID="NBK1342" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6122" />
                <XRef ID="6122" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301516</ID>
                <ID Source="BookShelf">NBK1342</ID>
              </Citation>
              <XRef ID="191" DB="Orphanet" />
              <XRef ID="C0009207" DB="MedGen" />
              <XRef ID="MONDO:0016006" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1854166" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="NM_005236.2_16_Deletion (entire coding sequence)|MedGen:C3808988;C0268140;C0009207" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000959872" DateUpdated="2024-06-09" DateCreated="2019-08-14" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-07-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9580660</ID>
          </Citation>
          <Comment>Loss-of-function variants in ERCC4 are known to be pathogenic (PMID: 9580660). A gross deletion of the genomic region encompassing the full coding sequence of the ERCC4 gene has been identified. The boundaries of this event are unknown as the deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. This variant has not been reported in the literature in individuals with ERCC4-related disease. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ERCC4" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.(?_14014013)_(14042214_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3808988" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268140" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0009207" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
          <SubmissionName>SUB5371970</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1854166" TraitType="Disease" MappingType="XRef" MappingValue="C0009207" MappingRef="MedGen">
        <MedGen CUI="C0009207" Name="Cockayne syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1854166" TraitType="Disease" MappingType="XRef" MappingValue="C0268140" MappingRef="MedGen">
        <MedGen CUI="C0268140" Name="Xeroderma pigmentosum, group F" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1854166" TraitType="Disease" MappingType="XRef" MappingValue="C3808988" MappingRef="MedGen">
        <MedGen CUI="C3808988" Name="Fanconi anemia complementation group Q" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

